Expert guidelines, based on research evidence, to help clinicians provide care. They are produced by bodies such as the British HIV Association (BHIVA), the European AIDS Clinical Society (EACS) and the World Health Organization (WHO).

Treatment guidelines: latest news

Treatment guidelines resources

  • When to start treatment

    Until recently, doctors weren’t sure of the best time to start HIV treatment. In 2015 a large, well-conducted study demonstrated that there are advantages to starting treatment as...

    From: Booklets

    Information level Level 2
  • Starting HIV treatment

    It’s better to start HIV treatment sooner, rather than later.Treatment will reduce the risk of HIV transmission, prevent illnesses and extend your life.A range of different antiretroviral...

    From: Factsheets

    Information level Level 2
  • When to start treatment

    Until recently, doctors weren’t sure of the best time to start HIV treatment. However in 2015 a large, well-conducted study demonstrated that there are advantages to starting...

    From: Booklets

    Information level Level 2
  • HIV treatment as prevention

    This briefing paper, produced by NAM for HIV Prevention England, describes the scientific evidence for HIV treatment as prevention and considers its implications for the UK....

    From: HIV prevention briefing papers

Treatment guidelines features

Treatment guidelines news from aidsmap

More news

Treatment guidelines news selected from other sources

  • What the Trans Community Needs to Know About New Expert Recommendations

    New provider recommendations aimed at doctors caring for trans patients were published on July 1 in the Annals of Internal Medicine, including changes that overall make it easier to identify trans patients and provide medical care for trans individuals.

    08 July 2019 | The Body
  • WHO’s “Treat All” Policy Had Immediate Effect on Global HIV Treatment Rates

    The World Health Organization (WHO) recommendation in 2015 that all nations provide HIV treatment regardless of an individual’s CD4 count had a rapid and stark effect on increasing rates of rapid access to antiretrovirals (ARVs) in various developing nations.

    04 July 2019 | POZ
  • American Heart Association Scientific Statement on CVD and HIV

    A new scientific statement from the American Heart Association (AHA) provides "pragmatic" recommendations on how to approach cardiovascular disease (CVD) prevention and management in the growing number of people living with HIV infection.

    04 June 2019 | Medscape (requires free registration)
  • As HIV patients live longer, heart disease might be their next challenge

    As people with HIV live longer, they also find themselves at higher risk for heart attack, stroke and other types of cardiovascular disease. A new American Heart Association report hopes to raise awareness about that connection, along with pointing out cardiovascular disease prevention and treatment strategies for an emerging population with unique concerns researchers have only begun to explore.

    04 June 2019 | American Heart Association
  • Medicare decides against tighter management of HIV drugs

    The Department of Health and Human Services will continue barring Medicare Part D plans from applying the drug utilization management tools prior authorization and step therapy for beneficiaries taking HIV antiretroviral drugs. A rule proposed in November 2018 would have permitted such practices. Gilead voiced opposition to the original proposal, saying physicians need to have the flexibility to prescribe the right medicines for patients.

    21 May 2019 | BioPharma Dive
  • U.S. Revises Pediatric HIV Treatment Guidelines

    Changes include new information about risks associated with Tivicay during pregnancy and a removal of older drugs owing to toxicities.

    23 April 2019 | Poz
  • Avoiding Dolutegravir in Young Women With HIV: Time for a Rethink?

    Total deaths for women with HIV and their children are projected to be lower with dolutegravir-based (Tivicay) antiretroviral therapy (ART) versus efavirenz-based (Sustiva) ART, a model-based analysis found.

    05 April 2019 | MedPage Today
  • For Our Stable HIV Patients, Why Are We Still Sending All These Lab Tests So Often?

    Do the guidelines for laboratory monitoring still make sense when our HIV treatments have become so safe and effective?

    29 January 2019 | NEJM Journal Watch
  • Dolutegravir- why new does not automatically mean better

    As has been previously reported by Spotlight, a new and exciting anti-retroviral, dolutegravir, is soon to become widely available in South Africa. Whilst its very real advantages have been extensively reported, the potential disadvantages have received relatively little attention.

    25 January 2019 | Spotlight
  • HIV care is threatened by proposed changes to Medicare Part D

    Optimal HIV care includes early and uninterrupted access to effective antiretroviral medications. Proposed changes to Medicare Part D threatens that.

    25 January 2019 | STAT
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.

See also

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.